Wednesday, August 07, 2019 9:40:52 AM
Under the terms of the Equity Agreement, following the effectiveness of a registration statement, the Company has the right to deliver from time to time a put notice to GHS stating the dollar amount of put shares (up to $400,000 under any individual notice) that it would sell to GHS. The Company expects to file its S-1 registration statement with the SEC within the next 30 days. Each put notice to GHS states the purchase price, the number of shares the Company is selling to GHS and the dollar amount GHS is to deliver to the Company within one day of receipt of the shares. The purchase price is calculated at eighty-five (85%) percent of the market price per share. The market price is calculated as the lowest closing price of the Company's common stock for ten (10) consecutive trading days preceding the put date. The Company is also obligated to issue to GHS an additional number of shares of Company common stock equal to 5% of each put amount.
Matthew Schissler, member of GHS, stated, “OZOP is unique and attractive to us on several levels. OZOP met our criterion for quality of management, quality of controls, and quality of business and business potential. We are very confident in the management team’s ability to continue to execute and we are excited to play a key role in the Company’s continued growth.”
Michael Chermak, Chief Executive Officer of OZOP, commented, “We are excited to have such a quality financing partner like GHS Investments to be part of the OZOP story. Since the Equity Agreement is on a look-back basis and there are no make-up provisions, this is truly a non-toxic equity investment. Proceeds received from the sale of common stock under this agreement will enable us to retire debt, including toxic convertible notes and continue to invest in our pipeline products.”
About Ozop Surgical Corp.
Ozop Surgical, Corp. (www.ozopsurgical.com) invents, designs, develops, manufactures and distributes innovative endoscopic instruments, surgical implants, instrumentation, devices and related technologies, focused on spine, neurological and pain management procedures and specialties. Our focus is on economically disrupting the market with clinically equivalent or superior existing and new products resulting in immediate and significant savings for providers, payors and consumers. For more information please visit www.ozopsurgical.com.
Recent OZSC News
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 01/29/2024 05:15:18 AM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 01/23/2024 09:59:05 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 01/12/2024 09:56:57 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/18/2023 08:15:19 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:00:50 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 03:33:21 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 07/07/2023 09:28:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/30/2023 09:24:00 PM
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM